Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125

被引:3
|
作者
Shirvani, Shervin M.
Kudchadker, Rajat J. [2 ]
Bruno, Teresa L. [2 ]
Likhacheva, Anna
Swanson, David A. [3 ]
Frank, Steven J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 97, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
关键词
Postimplant dosimetry; Prostate brachytherapy; Prostate cancer; Foley catheter; Catheterization; URETHRAL STRICTURES; CANCER;
D O I
10.1016/j.brachy.2010.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: Postoperative dosimetry is integral to quality assurance for prostate brachytherapy. Images on Day 0 are typically obtained with a contrast-filled urinary catheter in place for urethral dose calculations. However, expansion of the urethra and perhaps the prostate by the catheter may affect target coverage. We assessed. the effect of urinary catheterization on target dosimetry after implantation with palladium-103 ((103)Pd) or iodine-125 ((125)I) seeds. METHODS AND MATERIALS: Patients were 29 consecutive men with postimplant dosimetry calculated with and without a urinary catheter after brachytherapy seed implantation; 19 patients received (103)Pd seeds and 10 patients received (125)I seeds. In each case, 14-French caude tip urinary catheters were placed before implantation, and axial CT slices of the pelvis were obtained before and after catheter removal for postimplant dosimetry. Dosimetric parameters were measured and compared with paired Student's t tests. Trends were assessed by linear regression with the Pearson correlation coefficient. RESULTS: Removal of the urinary catheter significantly improved V(100) and D(90) for (103)Pd implants (mean +/- standard deviation (SD), 2.7% +/- 4.2%; range, -0.4% to 15%; p = 0.011 and mean +/- SD, 4.0% +/- 3.4%; range, -0.1% to 13.8%; p < 0.01, respectively). For (125)I implants, catheter removal improved D(90) (mean +/- SD, 1.5% +/- 1.8%; range, -1.3% to 4.2%; p = 0.027). For the (103)Pd group, the magnitude of change in V(100) correlated with prostate size (R(2) = 0.16) and source number (R(2) = 0.15). CONCLUSIONS: Urinary catheterization can artificially reduce target coverage after prostate implant brachytherapy. The patients undergoing (103)Pd implantation with smaller (<30 cm(3)) prostates and fewer (<90) sources are particularly susceptible to reduced D(90) and V(100) when a urinary catheter is present. (C) 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 50 条
  • [1] Prostate implant therapy: Iodine-125 versus palladium-103
    Peschel, RE
    CANCER JOURNAL, 2005, 11 (05): : 383 - 384
  • [2] American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103
    Rivard, Mark J.
    Butler, Wayne M.
    Devlin, Phillip M.
    Hayes, John K., Jr.
    Hearn, Robert A.
    Lief, Eugene P.
    Meigooni, Ali S.
    Merrick, Gregory S.
    Williamson, Jeffrey F.
    BRACHYTHERAPY, 2007, 6 (01) : 34 - 37
  • [3] MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy
    Hanania, Alexander N.
    Kudchadker, Rajat J.
    Bruno, Teresa L.
    Tang, Chad
    Anscher, Mitchell S.
    Frank, Steven J.
    BRACHYTHERAPY, 2020, 19 (01) : 38 - 42
  • [4] The comparison of biochemical disease-free survival between iodine-125 and palladium-103 brachytherapy for prostate cancer
    Park, TL
    Meek, AG
    Pai, S
    Xu, J
    Park, PK
    Pinsky, JJ
    RADIOLOGY, 2000, 217 : 212 - 213
  • [5] Investigation of the production routes of Palladium-103 and Iodine-125 radioisotopes
    Uncu, Yigit Ali
    Ozdogan, Hasan
    Sekerci, Mert
    Kaplan, Abdullah
    RADIATION PHYSICS AND CHEMISTRY, 2023, 204
  • [6] Long-term complications with prostate implants: Iodine-125 vs. palladium-103
    Peschel, RE
    Chen, Z
    Roberts, K
    Nath, R
    RADIATION ONCOLOGY INVESTIGATIONS, 1999, 7 (05): : 278 - 288
  • [7] Iodine-125 vs. palladium-103: Long-term complications
    Potters, L
    INTERNATIONAL JOURNAL OF CANCER, 2000, 90 (02) : 110 - 110
  • [8] Palladium-103 brachytherapy for prostate carcinoma
    Blasko, JC
    Grimm, PD
    Sylvester, JE
    Badiozamani, KR
    Hoak, D
    Cavanagh, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04): : 839 - 850
  • [9] Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
    Onishi, Kenta
    Tanaka, Nobumichi
    Miyake, Makito
    Nakai, Yasushi
    Anai, Satoshi
    Torimoto, Kazumasa
    Yamaki, Kaori
    Asakawa, Isao
    Hasegawa, Masatoshi
    Fujii, Tomomi
    Konishi, Noboru
    Fujimoto, Kiyohide
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2019, 14 : 51 - 58
  • [10] Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy
    Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, Netherlands
    不详
    Int. J. Radiat. Oncol. Biol. Phys., 4 (1072-1079):